Characteristics, pathways & outcomes of adults with R/R ALL
Research type
Research Study
Full title
A1. Characteristics, survival, treatment pathways, and healthcare resource use in adult patients with relapsed or refractory acute lymphoblastic leukaemia: a non-interventional study using secondary healthcare data from England.
IRAS ID
290366
Contact name
Myriam Alexander
Contact email
Sponsor organisation
Gilead Sciences Ltd
Duration of Study in the UK
0 years, 3 months, 4 days
Research summary
This is a retrospective, non-interventional cohort study based on secondary use of electronic hospital medical records. This is a study on patients with acute lymphoblastic leukaemia (aLL) and relapsed/refractory acute lymphoblastic leukaemia (R/RaLL)to describe their demographics and their characteristics and clinical outcomes. This study will be conducted in the English NHS secondary settings and gaining insight from 3 cohorts, focusing on Hospital Episodes Statistics (HES), the Systemic Anti-Cancer Therapy Database (SACT) and the Cancer Registry (CR). Information will be gathered from these databases to form 3 analysis groups.\nThe population for this study is adult patients diagnosed with acute lymphoblastic leukaemia.\nThe study is based on retrospective collection of data from patients electronic medical records.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
20/SC/0455
Date of REC Opinion
31 Dec 2020
REC opinion
Favourable Opinion